SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC
作者
Guillem Argilés,Johanna C. Bendell,Tae Gyun Kim,Matthew J. Wongchenko,Kelly DuPree,Sami Mahrus,X. Qu,Y. Shi,Anne R. Uyei,L. Roberts,Yingyan Yan,Fortunato Ciardiello